Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
Authors
Keywords
-
Journal
CANCER
Volume 128, Issue 22, Pages 3995-4003
Publisher
Wiley
Online
2022-09-16
DOI
10.1002/cncr.34457
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
- (2022) Don Husereau et al. BMJ-British Medical Journal
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
- (2021) Chi-Leung Chiang et al. Cancers
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
- (2021) Dan Su et al. JAMA Network Open
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- (2021) Xin Zhang et al. JAMA Network Open
- Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- (2021) Rui Pei et al. JAMA Network Open
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
- (2019) Enrique Soto-Perez-de-Celis et al. Journal of the National Comprehensive Cancer Network
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
- (2018) Amir Shlomai et al. PLoS One
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
- (2017) Leslie Wilson et al. THYROID
- Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
- (2016) J. Amdahl et al. Current Oncology
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling
- (2016) Claire Williams et al. MEDICAL DECISION MAKING
- Toward a Shared Vision for Cancer Genomic Data
- (2016) Robert L. Grossman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- The economic burden of brain metastasis among lung cancer patients in the United States
- (2016) A. Guérin et al. JOURNAL OF MEDICAL ECONOMICS
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
- (2015) Joong-Won Park et al. LIVER INTERNATIONAL
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective
- (2013) Chunyu Li et al. SUPPORTIVE CARE IN CANCER
- The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions
- (2013) Seema Kacker et al. TRANSFUSION
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States
- (2011) Dipen A. Patel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast Cancer
- (2011) Sophie Lauzier et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic evaluation of sorafenib in unresectable hepatocellular carcinoma
- (2010) Brian I. Carr et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
- (2010) Richard S. Finn et al. LIVER INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now